GP369
GP369 is a humanized FGFR2-IIIb-specific antibody. GP369 significantly inhibits the proliferation of tumor cells. GP369 can significantly inhibit phosphorylation of FGFR2 and downstream signaling pathways. GP369 can be used for research on cancer such as gastric cancer and breast cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
|
FGFR2 |
GP369 (0.001-1000 nM, 2-5 days) can significantly inhibit the proliferation of various cells, including FDCP-1, SUM52PE and MCF7 cells[1].
GP369 (0.001-100 nM, 2 days) inhibits FGFR2 IIIb driven proliferation and has no effect on FGFR2 IIIc in FDCP-1 (IC50 = 1.4 nM) cells[1].
GP369 (30 μg/mL, 3 days) inhibits proliferation induced by FGF7 (25 ng/mL) in MCF7 cells[1].
GP369 (10 μg/mL, 1-48 h) suppresses FGFR2 and ERK1/2 phosphorylation and downstream signaling in Ba/F3 and SNU-16 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:FDCP-1 cells
-
Concentration:0.001-100 nM
-
Incubation Time:2 days
-
Result:Significantly inhibited FGFR2 IIIb driven proliferation, including FGFR2 IIIb WT, FGFR2 IIIb N550K and FGFR2 IIIb S252W.
-
Cell Line:SNU-16 cells
-
Concentration:10 μg/mL
-
Incubation Time:2, 6, 24 and 48 h
-
Result:Reduced the level of FGFR2 protein.
-
Cell Line:Ba/F3 cells and SNU-16 cells
-
Concentration:5 μg/mL
-
Incubation Time:Incubated for 1 h and then combinated with FGF7 for 15 min
-
Result:Significantly inhibited FGF7 induced phosphorylation and downstream protein levels, including p-FGFR and p-ERK1/2.
GP369 (20 mg/kg, i.p.; twice weekly; for 27 days) realizes tumor arrest and significantly reduces FGFR2 phosphorylation and protein levels in NCr nude mice bearing MFM-223 xenografts[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C.B-17 SCID mice bearing 5×106 SNU-16 cells (10 weeks)[1]
-
Dosage:2, 5, 10 and 20 mg/kg
-
Administration:Intraperitoneal injection (i.p.); twice weekly for 43 days
-
Result:Significantly inhibited tumor volume.
Significantly reduced the levels of FGFR2 and p-FGFR.
-
Animal Model:1×107 MFM-223 cells injected female NCr nude mice (5 weeks)[1]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection (i.p.); twice weekly for 27 days
-
Result:Significantly inhibited tumor volume.
Significantly reduced the levels of FGFR2 and p-FGFR.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
N/A
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz